Page 5 - Phase 3 News Today

Company Continues Enrollment in Key Trials, Prioritizes Phase 3 Trial with ARV-766, and Reports Cash Position of $1,004.0 Million

Trial data support multiple switching between biosimilar and reference product over a 48-week course for the treatment of psoriasis.

Primary results presented at ASN Kidney Week 2023 showed spironolactone missed the trial's primary endpoint.

Atrasentan demonstrated superiority versus placebo for reduction in proteinuria through 36 weeks.

Kremer discusses new ad hoc findings from the phase 3 ENHANCE trial showing seladelpar's unique effect on pruritus in patients with PBC.

Results showed higher-exposure dupilumab met the study’s primary endpoint for peak esophageal intraepithelial count ≤6 eos/high-power field.

New data from ACG 2023 shows etrasimod-treated patients were able to achieve UC remission, with or without concomitant steroid treatment at baseline.

New QUASAR analysis shows patients with intolerance or failed response to advanced therapies nonetheless achieved benefit with guselkumab.

REGULATED INFORMATION Following the in-principle agreement reached with its main creditors in the context of ongoing equity raise process, the focus of BioSenic is now to proceed with fundraising, allowing to start its phase 3 international clinical trial with oral arsenic trioxide (ATO) in the first-line treatment of chronic Graft-versus-Host-Disease (cGvHD). Mont-Saint-Guibert, Belgium, October 25, 2023, 7.00 am CEST – BioSenic provides third quarter 2023 Business Update Following the i...

Investigator Brian E. Lacy, MD, PhD discusses new post hoc analysis that he hopes will provided clearer expectations for timing of benefit with tenapanor.